RecruitingObesity

Cannabis for Obesity Trial

Eligible age

18–65 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

The goal of this study is to determine the initial efficacy of once daily oral cannabis for weight loss in obese individuals.

Sponsor: Joshua A. Lile, Ph.D.

✓ Male or female.
✓ Age 18-65 years.
✓ BMI \>=30 kg/m2 (i.e., obese).
✓ In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations at Screening and/or Check-in as assessed by one of the MD study personnel.
✓ Able to speak and read English.
✓ Apple or Android phone, or Android tablet with wi-fi or cellular service.
✓ Vital signs at Screening and Check-in as per the following ranges and stable (measured in a supine position after a minimum of 5 minutes of rest):
✓ Systolic blood pressure ≥ 90 and ≤ 140 mmHg

✕ UK Students cannot participant
✕ Current cannabis use (e.g., past month; negative test for cannabinoids during screening) and no more than 15 self-reported lifetime uses.
✕ Self-reported current use of CBD.
✕ Severe past negative experience with cannabis or cannabinoid use (e.g., panic attack, anxiety).
✕ Use of any anti-obesity medication in the past 90 days. Specifically GLP-1 agonists (e.g., liraglutide, semaglutide, tirzepatide), SGLT-2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), sulfonylureas (e.g., glimepiride, glipizide), medlitinides (e.g., repaglinide, nateglinide), Contrave, phentermine (alone or combination product such as Qsymia) or Orlistat. Stable use of metformin is permitted.
✕ Current treatment with insulin.
✕ History of type 1 diabetes.
✕ Stable body weight over the past 3 months. No changes greater than 5 kg.

Lexington

Source: ClinicalTrials.gov · NCT06137365 · last updated 2026-08-07